{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:19:47Z","timestamp":1762607987747},"reference-count":37,"publisher":"The Japanese Society of Nuclear Cardiology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.17996\/anc.20-00115","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T22:04:48Z","timestamp":1596060288000},"page":"53-60","source":"Crossref","is-referenced-by-count":1,"title":["Radionuclide Imaging for Cardiac Sarcoidosis: Much Potential Benefit, but Still Much to Do"],"prefix":"10.17996","volume":"6","author":[{"given":"Mark I.","family":"Travin","sequence":"first","affiliation":[{"name":"Department of Radiology\/Division of Nuclear Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7364","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68: 411\u201321.","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"2","unstructured":"2. Hulten E, Aslam S. Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther 2016; 6: 50\u201363."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of <sup>18<\/sup>F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol 2017; 24: 1741\u201358.","DOI":"10.1007\/s12350-017-0978-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kumita S, Yoshinaga K, Miyagawa M, et al.; Committee for diagnosis of cardiac sarcoidosis using <sup>18<\/sup>F-FDG PET, Japanese Society of Nuclear Cardiology. Recommendations for <sup>18<\/sup>F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis- 2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol 2019; 26: 1414\u201333.","DOI":"10.1007\/s12350-019-01755-3"},{"key":"5","unstructured":"5. Hiraga H, Iwai K. Guidelines for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary disease (in Japanese). Tokyo: The Japanese Ministry of Health, Labour and Welfare, 1993: 23\u20134."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol 2018; 25: 1136\u201346.","DOI":"10.1007\/s12350-016-0658-1"},{"key":"7","unstructured":"7. Hiraga H, Yuwai K, Hiroe M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis and Granulomatous Disorders (in Japanese) 2007; 27: 89\u2013102."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014; 28: 393\u2013403.","DOI":"10.1007\/s12149-014-0806-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol 2017; 3: 42\u20135.","DOI":"10.17996\/anc.17-00042"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1304\u201323.","DOI":"10.1016\/j.hrthm.2014.03.043"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med 2019; 60: 892\u20138.","DOI":"10.2967\/jnumed.119.228130"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography\/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 2018; 11: e007030.","DOI":"10.1161\/CIRCIMAGING.117.007030"},{"key":"13","unstructured":"13. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with <sup>13<\/sup>N-NH<sub>3<\/sub>\/<sup>18<\/sup>F-FDG PET. J Nucl Med 2003; 44: 1030\u20136."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on <sup>18<\/sup>Ffluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538\u201343.","DOI":"10.1093\/eurheartj\/ehi180"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Youssef G, Leung E, Mylonas I, et al. The use of <sup>18<\/sup>F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and meta-analysis including the Ontario experience. J Nucl Med 2012; 53: 241\u20138.","DOI":"10.2967\/jnumed.111.090662"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Writing group; Document reading group; EACVI Reviewers: This document was reviewed by members of the EACVI Scientific Documents Committee for 2014\u20132016 and 2016\u20132018. A joint procedural position statement on imaging in cardiac sarcoidosis: From the Cardiovascular and Inflammation &amp; Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging. 2017; 18: 1073\u201389.","DOI":"10.1093\/ehjci\/jex146"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bravo PE, Singh A, Di Carli MF, Blankstein R. Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2019; 26: 188\u201399.","DOI":"10.1007\/s12350-018-01488-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329\u201336.","DOI":"10.1016\/j.jacc.2013.09.022"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lee PI, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2017; 24: 19\u201328.","DOI":"10.1007\/s12350-016-0682-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis. J Nucl Cardiol 2017; 24: 413\u201324.","DOI":"10.1007\/s12350-016-0490-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Keijsers RGM, van den Heuvel DAF, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2013; 41: 743\u201351.","DOI":"10.1183\/09031936.00088612"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kruse MJ, Kovell L, Kasper EK, et al. Myocardial blood flow and inflammatory cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10: 157\u201367.","DOI":"10.1016\/j.jcmg.2016.09.023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cooper LT, Baughman KL, Feldman AM, et al. The role of endocardialbiopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007; 28: 3076\u201393.","DOI":"10.1093\/eurheartj\/ehm456"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Osborne MT, Hulten EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2017; 24: 86\u201399.","DOI":"10.1007\/s12350-016-0502-7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting <sup>18<\/sup>F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16: 801\u201310.","DOI":"10.1007\/s12350-009-9110-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial <sup>18<\/sup>F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016; 23: 244\u201352.","DOI":"10.1007\/s12350-015-0226-0"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Larson SR, Pieper JA, Hulten EA, et al. Characterization of a highly effective preparation for suppression of myocardial glucose utilization. J Nucl Cardiol 2019. doi: 10.1007\/s12350-019-01786-w. [Epub ahead of print]","DOI":"10.1007\/s12350-019-01786-w"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Christopoulos G, Jouni H, Acharya GA, et al. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol. J Nucl Cardiol 2019. doi: 10.1007\/s12350-019-01746-4. [Epub ahead of print]","DOI":"10.1007\/s12350-019-01746-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016; 23: 1187\u2013226.","DOI":"10.1007\/s12350-016-0522-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ohira H, Birnie DH, Pena E, et al. Comparison of <sup>18<\/sup>F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2016; 43: 259\u201369.","DOI":"10.1007\/s00259-015-3181-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sperry BW, Tamarappoo BK, Oldan JD, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on <sup>18<\/sup>F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2018; 11: 336\u201345.","DOI":"10.1016\/j.jcmg.2017.04.020"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010; 3: 1219\u201328.","DOI":"10.1016\/j.jcmg.2010.09.015"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Manabe O, Ohira H, Hirata K, et al. Use of <sup>18<\/sup>F-FDG PET\/CT texture analysis to diagnose cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2019; 46: 1240\u20137.","DOI":"10.1007\/s00259-018-4195-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Smedema JP, Snope G, van Kroonenburgh MPG, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45: 1683\u201390.","DOI":"10.1016\/j.jacc.2005.01.047"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with <sup>18<\/sup>F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933\u201341.","DOI":"10.1007\/s00259-007-0650-8"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bateman TM. Cardiac sarcoidosis: an important niche for PET, but a journey just begun. J Nucl Cardiol 2017; 24: 425\u20138.","DOI":"10.1007\/s12350-016-0624-y"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Garg G, Cohen S, Neches R, Travin MI. Cardiac <sup>18<\/sup>F-FDG uptake in Chagas disease. J Nucl Cardiol 2015; 23: 321\u20135.","DOI":"10.1007\/s12350-015-0218-0"}],"container-title":["Annals of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/anc\/6\/1\/6_20-00115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T04:01:04Z","timestamp":1599278464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/anc\/6\/1\/6_20-00115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.17996\/anc.20-00115","relation":{},"ISSN":["2189-3926","2424-1741"],"issn-type":[{"value":"2189-3926","type":"print"},{"value":"2424-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}